The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A multicenter, phase II clinical trial.
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Akitaka Makiyama
Speakers' Bureau - Chugai Pharma; Lilly; Takeda
 
Yuji Miyamoto
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hirofumi Kawanaka
No Relationships to Disclose
 
Keisuke Miwa
No Relationships to Disclose
 
Akira Kabashima
No Relationships to Disclose
 
Masahiro Hamanoue
No Relationships to Disclose
 
Takafumi Ohchi
No Relationships to Disclose
 
Tomomi Kashiwada
Speakers' Bureau - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical
 
Mototsugu Shimokawa
Consulting or Advisory Role - Sysmex
 
Hiroshi Saeki
No Relationships to Disclose
 
Yoshito Akagi
No Relationships to Disclose
 
Hideo Baba
Honoraria - Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Masaki Mori
Speakers' Bureau - Chugai Pharma; Taiho Pharmaceutical